Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Paulette Mattson"'
Autor:
Walburga Engel-Riedel, Jamie Lowe, Paulette Mattson, J. Richard Trout, Richard D. Huhn, Michele Gargano, Myra L. Patchen, Richard Walsh, My My Trinh, Mariève Dupuis, Folker Schneller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract Background BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncology antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and sa
Externí odkaz:
https://doaj.org/article/a97a56be9beb405a92afcd70845c53f1
Autor:
Mark T. Uhlik, Jamie Lowe, Maysa M. Abu-Khalaf, Jeremy R. Graff, Paulette Mattson, K Breuer, Michele Gargano, Alison Stopeck, Virginia F. Borges, Ruta D. Rao, Bruno Osterwalder, Joanna Cox, Nandita Bose, Bartosz Chmielowski, Steven J. O'Day, Michael Chisamore
Publikováno v:
Cancer Research. 79:P2-09
Background: CPI monotherapy provides substantial clinical benefit to patients (pts) in multiple cancers, yet response rates are limited (˜15-30%) and fails to benefit the majority. In these pts there is limited or no ongoing T cell-based immune resp
Autor:
Meredith Pelster, Marcio Torre, Geoffrey Sumithran Kannan, Michele Anne Gargano, Paulette Mattson, Blaine Rathmann, Nandita Bose, Jose Luis Iglesias
Publikováno v:
Journal of Clinical Oncology. 40:TPS3179-TPS3179
TPS3179 Background: To survive harsh tumor microenvironments, cancer cells actively utilize ISR as an adaptive stress response and survival mechanism. General control nonderepressible 2 (GCN2), a serine-threonine kinase is essential for maintaining c
Autor:
Richard Walsh, Xiaohong Qiu, Mark Uhlik, Paulette Mattson, Michele Gargano, Nadine Ottoson, Anissa S.H. Chan, Nandita Bose, Ben J. Harrison, Jeremy R. Graff, Joanna Cox, Michael Chisamore
Publikováno v:
Poster Presentations.
Background Checkpoint inhibitor (CPI) monotherapies, including pembrolizumab (KEYTRUDA®, pembro), avelumab and atezolizumab have demonstrated modest clinical benefit in chemotherapy-relapsed/refractory TNBC patients (pts) with ~5-10% response rate,
Autor:
Anissa Chan, Nandita Bose, Nadine Ottoson, Xiaohong Qiu, Ben Harrison, Richard Walsh, Paulette Mattson, Michele Gargano, Joanna Cox, Michael Chisamore, Mark Uhlik, Jeremy Graff
Publikováno v:
Poster Presentations.
Background Checkpoint inhibitor (CPI) monotherapy has revolutionized the treatment of melanoma, yet most patients are primary nonresponders or develop secondary resistance. Lack of antigen-specific T cell priming and/or immunosuppressive mechanisms l
Autor:
Jeremy R. Graff, Nandita Bose, Vassiliki Karantza, Michele Gargano, Mark Uhlik, Ruta D. Rao, Virginia F. Borges, Bartosz Chmielowski, Alison Stopeck, Paulette Mattson, Joyce O'Shaughnessy, Steven J. O'Day, Maysa M. Abu-Khalaf, Bruno Osterwalder, Michael Chisamore, Joanna Cox
Publikováno v:
Cancer Research. 80:CT073-CT073
Background: Immune checkpoint inhibitor (ICI) monotherapy shows limited benefit in metastatic triple negative breast cancer (mTNBC) patients (pts), particularly in the second line + setting (ORR ~5-6%, mOS 9 months). In the recent Keynote-119 phase 3
Autor:
Bruno Osterwalder, Joanna Cox, Ruta D. Rao, Virginia F. Borges, Melinda L. Telli, Montaser Shaheen, Vassiliki Karantza, Nandita Bose, Paulette Mattson, Michael Chisamore, Michele Gargano, Petros Nikolinakos, Mark Uhlik, Maysa M. Abu-Khalaf, Bin Xie, Steven J. O'Day, Bartosz Chmielowski, Jeremy R. Graff, Alison Stopeck
Publikováno v:
Journal of Clinical Oncology. 37:2550-2550
2550 Background: Checkpoint inhibitor (CPI) monotherapy shows limited clinical response in previously treated mTNBC patients (pts) (Table). Agents are needed that extend this benefit to more mTNBC pts. PGG is a novel, IV administered PAMP that, in pt
Autor:
Alison Stopeck, Paulette Mattson, Michael Chisamore, Richard D. Huhn, B Ma, Mark T. Uhlik, Jeremy R. Graff, R Prathikanti, Nandita Bose, Michele Gargano, Katie Ertelt, Steven J. O'Day, Jamie Lowe, Nadine Ottoson
Publikováno v:
Cancer Research. 78:OT1-01
By blocking the interaction of PD-L1 with PD-1, immune checkpoint inhibitors (CPI) can unleash specific, anti-cancer killing function of activated cytotoxic T cells in patients (pts) for whom there is evidence of an ongoing anti-cancer immune respons
Autor:
Richard D. Huhn, Mable Ma, Michael Chisamore, Richard Walsh, Steven J. O'Day, Nandita Bose, Jeremy R. Graff, Steven M. Leonardo, Bruno Osterwalder, Michele Gargano, Paulette Mattson, Mark Uhlik, Radha Prathikanti, Ben J. Harrison, Jamie Lowe, Katie Ertelt, Xiaohong Qiu, Nadine Ottoson
Publikováno v:
Molecular Cancer Therapeutics. 17:LB-A31
Imprime PGG (Imprime) is a novel immunotherapeutic that acts as a non-self danger signal to activate the innate immune system and coordinate an adaptive immune system response. In multiple preclinical tumor models, Imprime significantly enhances anti
Autor:
Jamie Lowe, Michael Chisamore, Mark T. Uhlik, Nandita Bose, Paulette Mattson, Nadine Ottoson, Jose Iglesias, Jeremy R. Graff, Richard D. Huhn, Katie Ertelt, Bo Ma, Deb Kedrowski, Radha Prathikanti
Publikováno v:
Journal of Clinical Oncology. 35:TPS3105-TPS3105
TPS3105 Background: Imprime PGG (Imprime) is a Pathogen- Associated Molecular Pattern that enhances innate immune cell killing, counteracts immune suppression and triggers activation and maturation of antigen presenting cells. Imprime’s ability to